Deep Medicine Acquisition - Tradeable Rights - Oct 2026 Profit Margin

Deep Medicine Acquisition - Tradeable Rights - Oct 2026 posts a profit margin of -55.68% as of June 2026. That compares with -52.55% in the prior-year period — down 5.9% year over year. That is below the sector sector average of 21.34%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Deep Medicine Acquisition - Tradeable Rights - Oct 2026's profit margin was -52.55%. The latest reading is -55.68% — a 5.9% year-over-year decrease (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

For its sector stocks, a profit margin near 21.34% is typical. Deep Medicine Acquisition - Tradeable Rights - Oct 2026's -55.68% is lower that level. That is roughly 360.9% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Deep Medicine Acquisition - Tradeable Rights - Oct 2026's profit margin moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is -55.68% as of June 2026; use YoY and peer views to separate noise from signal.

Context for DMAQR's profit margin usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 21.34%), and (3) consistency with growth and profitability. This page covers the first two; Deep Medicine Acquisition - Tradeable Rights - Oct 2026's other metric pages and overview cover the third.